Desmoda is a drug owned by Eton Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 03, 2044. Details of Desmoda's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12343372 | Desmopressin Oral Compositions |
Apr, 2044
(17 years from now) | Active |
| US12214010 | Desmopressin Oral Compositions |
Apr, 2044
(17 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Desmoda is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Desmoda's family patents as well as insights into
ongoing legal events
on those patents.
Desmoda's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Desmoda's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 03, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Desmoda Generic API suppliers:
Desmopressin Acetate is the generic name for the brand Desmoda. 23 different companies have already filed for the generic of Desmoda, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Desmoda's generic
Alternative Brands for Desmoda
There are several other brand drugs using the same active ingredient (Desmopressin Acetate) as Desmoda. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Acerus Pharms |
| |||
| Ferring |
| |||
| Ferring Pharms Inc |
| |||
| Nordic Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Desmopressin Acetate, Desmoda's active ingredient. Check the complete list of approved generic manufacturers for Desmoda
About Desmoda
Desmoda is a drug owned by Eton Pharmaceuticals Inc. Desmoda uses Desmopressin Acetate as an active ingredient. Desmoda was launched by Eton in 2026.
Approval Date:
Desmoda was approved by FDA for market use on 25 February, 2026.
Active Ingredient:
Desmoda uses Desmopressin Acetate as the active ingredient. Check out other Drugs and Companies using Desmopressin Acetate ingredient
Dosage:
Desmoda is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05MG/ML | SOLUTION | Prescription | ORAL |